AngioDynamics, Inc. (ANGO)
| Market Cap | 539.78M +20.2% |
| Revenue (ttm) | 313.73M +10.7% |
| Net Income | -31.39M |
| EPS | -0.76 |
| Shares Out | 41.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 408,532 |
| Open | 12.44 |
| Previous Close | 12.37 |
| Day's Range | 12.43 - 13.16 |
| 52-Week Range | 8.36 - 13.99 |
| Beta | 0.36 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+39.0%) |
| Earnings Date | Jul 14, 2026 |
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device tha... [Read more]
Financial Performance
In fiscal year 2025, AngioDynamics's revenue was $292.50 million, a decrease of -3.76% compared to the previous year's $303.91 million. Losses were -$33.99 million, -81.56% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 39.00% from the latest price.
News
AngioDynamics receives FDA IDE approval for RELIEF feasibility study
AngioDynamics (ANGO) announced that the U.S. Food and Drug Administration, FDA, has approved the Company’s Investigational Device Exemption, IDE, application to initiate the RELIEF study. RELIEF is a ...
AngioDynamics Receives FDA IDE Approval for RELIEF Feasibility Study Evaluating NanoKnife IRE Platform as Minimally Invasive Treatment for Benign Prostatic Hyperplasia (BPH)
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company has transformed to focus on high-growth cardiovascular and oncology markets, with innovative products like Auryon and NanoKnife driving double-digit growth and market share gains. Strong clinical results, favorable reimbursement, and a robust pipeline support continued expansion.
AngioDynamics Slides: FY 2026
AngioDynamics has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 10, 2026.
AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
3 Unknown Small-Cap Stocks with ‘Strong Buy’ Ratings and Up to 70% Upside in 2026
Small-cap stocks often go unnoticed, but a few are grabbing Wall Street’s attention. Analysts are highlighting Septerna, Inc. ($SEPN), Kornit Digital ($KRNT), and AngioDynamics ($ANGO) as companies wi...
AngioDynamics announces two-year PRESERVE trial data
AngioDynamics (ANGO) announced two-year results from the PRESERVE pivotal trial demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of...
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has transformed its portfolio, focusing on high-growth MedTech segments and innovative devices for cardiovascular and oncology markets. Strong financials, ongoing product innovation, and market expansion position it for sustained growth and margin improvement.
AngioDynamics initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of AngioDynamics (ANGO) with a Buy rating and $16 price target The firm sees an improved growth profile for the company due to its pivot to…
AngioDynamics price target lowered to $16 from $18 at Canaccord
Canaccord lowered the firm’s price target on AngioDynamics (ANGO) to $16 from $18 and keeps a Buy rating on the shares. The firm said they delivered a good FQ3 with…
AngioDynamics Earnings Call Transcript: Q3 2026
Third quarter revenue grew 8.9% year-over-year, led by MedTech segment strength and robust growth in Auryon, AlphaVac, and NanoKnife. Full-year guidance for net sales and adjusted EBITDA was raised for the third consecutive quarter, with strong cash and no debt.
AngioDynamics Quarterly report: Q3 2026
AngioDynamics has published its Q3 2026 quarterly earnings report on April 2, 2026.
AngioDynamics Earnings release: Q3 2026
AngioDynamics released its Q3 2026 earnings on April 2, 2026, summarizing the period's financial results.
AngioDynamics Slides: Q3 2026
AngioDynamics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on April 2, 2026.
AngioDynamics reports Q3 adjusted EPS (7c), consensus (11c)
Reports Q3 revenue $78.4M, consensus $76.77M. “We delivered a strong quarter, driven by continued execution across the organization, allowing us to deliver yet another quarter of profitable growth,” c...
AngioDynamics narrow FY26 EPS view to (30c)-(23c) from (33c)-(23c)
FY26 EPS consensus (29c). Raises FY26 revenue view to $313.5M-$315.5M from $312M-$314M, consensus $312.88M.
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Transcript: Leerink Global Healthcare Conference 2026
The business has transformed into a tech-focused med tech company, driving strong growth in cardiovascular and oncology platforms. Med Tech products are outperforming expectations, with Auryon and AlphaVac leading expansion, while NanoKnife is gaining traction in prostate cancer and BPH. Robust R&D and a growing sales force support continued momentum.
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...